Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV
Charles River Laboratories to acquire CROs Argenta and BioFocus.
Charles River Laboratories has entered into an agreement to acquire the CRO services division of Galapagos NV, which includes both Argenta and BioFocus. These businesses offer integrated drug discovery services, with a focus on in-vitro capabilities. The acquisition will help position Charles River as a full service, early-stage CRO, with integrated in-vitro and in-vivo capabilities from target discovery through preclinical development. The purchase price is €129 million (approximately $179 million), and the transaction includes future performance payments of up to €5 million (approximately $7 million).
Located in the United Kingdom and the Netherlands, Argenta and BioFocus provide a full suite of drug discovery services from target discovery through the delivery of clinic-ready candidates to a broad range of pharmaceutical and biotechnology companies.
Source: Charles River Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
